Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Oxycodone Drugs Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The market for oxycodone pharmaceuticals has seen robust expansion in recent years. Projected to increase from $5.98 billion in 2025 to $6.38 billion in 2026, this represents a compound annual growth rate (CAGR) of 6.7%. Factors driving this historical growth include a significant prevalence of moderate to severe pain conditions, extensive use of opioids for postoperative care, substantial hospital demand for injectable pain relievers, well-established clinical effectiveness of oxycodone, and a scarcity of alternative pain management options.
The market for oxycodone drugs is projected to see considerable expansion in the years ahead. By 2030, its size is forecasted to reach $8.07 billion, expanding at a compound annual growth rate (CAGR) of 6.1. This growth during the forecast period can be explained by the implementation of tighter opioid prescribing rules, the rise of controlled-release pain management approaches, an increasing incidence of cancer and chronic pain conditions, the proliferation of dedicated pain management clinics, and progress in creating safer opioid formulations. Among the major trends expected in this period are a movement toward abuse-deterrent oxycodone versions, growing use of extended-release pain therapies, a higher preference for administering opioids in hospital settings, an amplified focus on prescription tracking and adherence, and the widening availability of generic oxycodone products within regulated markets.
Download A Free Sample Report For Comprehensive Market Insights:
Oxycodone Drugs Market Industry Drivers: What Is Driving Revenue Growth?
The increasing prevalence of orthopedic conditions is anticipated to drive expansion in the oxycodone drug market moving forward. These disorders involve the bones, joints, ligaments, tendons, and muscles, frequently leading to persistent pain, decreased movement, and long-term physical limitations. This rise in orthopedic cases is fueled by aging populations, inactive lifestyles, obesity, sports injuries, and work-related strain. Oxycodone medications assist in effective pain management by alleviating both acute and chronic orthopedic discomfort—such as that from fractures, joint issues, or post-operative recovery—by acting on central nervous system pain receptors. In February 2024, Arthritis Australia, a non-profit organization based in Australia, reported that by 2025, an estimated 212,136 men and 362,137 women are expected to have rheumatoid arthritis (RA), with these figures projected to grow to around 280,040 men and 479,828 women by 2040. As a result, the growing burden of orthopedic disorders is fueling the growth of the oxycodone drug market.
Oxycodone Drugs Market Segment Performance And Strategic Opportunities
The oxycodone drugs market covered in this report is segmented –
1) By Drug Type: Short Acting Oxycodone, Long Acting Oxycodone
2) By Dosage Form: Tablets, Capsules, Injections
3) By Indication: Neuropathic Pain, Musculoskeletal Pain, Cancer Pain, Post Operative Pain, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Short Acting Oxycodone: Immediate-Release Oxycodone Tablets, Oxycodone Oral Solution
2) By Long Acting Oxycodone: Extended-Release Oxycodone Tablets, Oxycodone Controlled-Release Formulations
Oxycodone Drugs Market Growth Trends: What Is Influencing The Future Outlook?
Leading firms within the oxycodone drug market are increasingly concentrating on creating sophisticated abuse-deterrent immediate-release (IR) formulations to minimize the potential for misuse through injection or intranasal administration. These abuse-deterrent IR products are designed with physical and chemical barriers, making it challenging to crush, dissolve, or alter the tablets for non-oral use, which boosts patient safety and reduces the likelihood of drug diversion. A notable example is from October 2024, when Protega Pharmaceuticals LLC, a pharmaceutical company based in the US, secured FDA approval for ROXYBOND™ (oxycodone hydrochloride) 10 mg immediate-release tablets. These tablets feature the patented SentryBond abuse-deterrent technology, which is specifically built to withstand both physical manipulation and chemical extraction, thereby preventing easy cutting, crushing, or dissolving for misuse via nasal or intravenous routes. Consequently, this approach reduces abuse potential while ensuring effective immediate-release pain management for patients whose severe pain requires opioid therapy, provided other treatment options have proven insufficient.
Oxycodone Drugs Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the oxycodone drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Purdue Pharma L.P, Endo International plc, Amneal Pharmaceuticals LLC, Mundipharma Pty Limited, Alkermes plc, Mallinckrodt Pharmaceuticals, Alvogen Group Inc., Collegium Pharmaceutical Inc., Lannett Company Inc., Acorda Therapeutics Inc., Camurus AB, Rhodes Pharmaceuticals L.P., KVK Tech Inc., Teikoku Pharma USA Inc., Manus Aktteva Biopharma LLP, Zyla Life Sciences
Access The Complete Oxycodone Drugs Market Report:
Oxycodone Drugs Market Regional Analysis And Leading Geography
North America was the largest region in the oxycodone drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oxycodone drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model